Prostate-specific antigen—all that rises is not refractory - 03/09/11
Doi : 10.1016/S0090-4295(01)00911-6
Brace L Hintz a, ⁎, Al Van Nieuwenhuize b, A.Robert Kagan a
a Department of Radiation Oncology, Southern California Permanente Medical Group, Los Angeles, California, USA
b Department of Urology, Southern California Permanente Medical Group, Bellflower, California, USA
*Address for correspondence: Brace L. Hintz, M.D., Department of Radiation Oncology, 4950 Sunset Boulevard (2-B), Los Angeles, CA 90027
Abstract |
After the initiation of androgen suppression in men with prostate cancer, the serum prostate-specific antigen (PSA) level generally declines. A subsequent PSA rise during that suppression usually reflects the presence of a significant component of hormonally refractory prostate cancer. We report a patient with a rising PSA level and elevated testosterone level after depot leuprolide in whom the PSA level subsequently declined with administration of bicalutamide.
Le texte complet de cet article est disponible en PDF.Plan
© 2001
Elsevier Science Inc. Tous droits réservés.
Vol 57 - N° 5
P. 975 - mai 2001 Retour au numéro
Article précédent
- Endoscopic retrieval of retained Jackson-Pratt drain
- Victor H Hartanto, Ken-Ryu Han, Murali Ankem, Stuart M Diamond
- A rare case of renal hemangioma presenting as polycythemia
- Benjamin J Leak, Javid Javidan, Rifaat Dagher
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?